U.S. FDA's banner
U.S. FDA's profile picture

U.S. FDA

@FDA591,734 subscribers

Our posts are FDA Approved! Privacy Policy - https://t.co/LbTJXYRXVP FDA Authentic Accounts - https://t.co/w2LNbzG7M0

Shorts

FDA proposes to exclude semaglutide, tirzepatide, and liraglutide on the 503B bulks list. After careful review, we did not identify sufficient clinical need for outsourcing facilities to compound these drugs from bulk substances. Public comment period now open. Learn more:

FDA proposes to exclude semaglutide, tirzepatide, and liraglutide on the 503B bulks list. After careful review, we did not identify sufficient clinical need for outsourcing facilities to compound these drugs from bulk substances. Public comment period now open. Learn more:

105,392 просмотров

Videos

Больше нет контента для загрузки